EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
7.10
-0.02 (-0.28%)
Dec 20, 2024, 4:00 PM EST - Market closed
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for EYPT stock have an average target of 24.5, with a low estimate of 15 and a high estimate of 33. The average target predicts an increase of 245.07% from the current stock price of 7.10.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for EYPT stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +209.86% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $22 | Strong Buy | Maintains | $30 → $22 | +209.86% | Nov 11, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $33 | Strong Buy | Maintains | $28 → $33 | +364.79% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 | Strong Buy | Maintains | $28 | +294.37% | Oct 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +322.54% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
43.60M
from 46.02M
Decreased by -5.25%
Revenue Next Year
15.72M
from 43.60M
Decreased by -63.95%
EPS This Year
-2.31
from -1.82
EPS Next Year
-2.72
from -2.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 59.9M | 25.0M | 48.9M | |||
| Avg | 43.6M | 15.7M | 8.8M | |||
| Low | 31.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 30.1% | -42.6% | 211.3% | |||
| Avg | -5.2% | -63.9% | -43.7% | |||
| Low | -32.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.91 | -2.16 | -2.14 | |||
| Avg | -2.31 | -2.72 | -3.02 | |||
| Low | -2.89 | -3.71 | -3.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.